Objective: This study, lasting up to 90 days, was undertaken in patients with osteoarthritis with persistent moderate to severe pain uncontrolled by standard therapy (nonsteroidal anti-inflammatory drugs, acetaminophen, and/or short-acting opioids) to evaluate functional outcomes, as well as efficacy and safety, of controlled-release oxycodone versus placebo.
O steoarthritis (OA) is defined as a heterogeneous group of conditions leading to signs and symptoms associated with defects in the integrity of the articular cartilage and underlying bone in joints and joint margins; hence, patients seek treatment due to joint pain and loss of function. 1, 2 The prevalence of OA is increasing as the population ages.
2,3 Prevalence rates for hip and knee OA vary depending upon whether diagnosis is made clinically or radiographically, and there is often discordance between radiographic evidence and patient reports of joint pain. 1, 4 It has been suggested that the origins of pain may be due to deterioration within the joint capsule, ligaments and insertions, periosteum and subchondral bone, and synovium. 4, 5 Although it has been shown that inflamed synovium contains an upregulated expression of opioid receptors, the exact source of OA pain is often unclear in the individual patient. [5] [6] [7] Nonetheless, it has been shown that pain in patients with OA is a better predictor of disability and impact on daily life than the diagnostic radiographic grade. 5, 8, 9 Most treatments of OA are not disease modifying and are directed at reducing pain, maintaining and/or improving joint mobility, and limiting functional impairment. 10 It is generally agreed that nonpharmacologic methods (eg, physical and occupational therapy, patient education) constitute the primary treatment, to be followed or accompanied by the use of drug therapy as needed. Additional interventions include the administration of intra-articular injections of hyaluronan (hyaluronic acid) or glucocorticoids. 10, 11 Initial analgesic therapy consists of acetaminophen (APAP), salicylates, and nonsteroidal antiinflammatory drugs (NSAIDs), including the recently available specific cyclo-oxygenase-2 (COX-2) inhibitors, or the weak opioids propoxyphene and tramadol, followed by the use of stronger opioids when other treatments are no longer effective. 11, 12 Acetaminophen and NSAIDs are known to be characterized by 2 types of dosing limitations: first, they exhibit a ceiling effect for analgesia; second, at higher doses, they have shown the potential for gastric, renal, and hepatic toxicitiescomplications that are of particular concern to the elderly, the population most likely to receive these analgesics. [13] [14] [15] [16] [17] [18] [19] [20] In addition, a recent randomized placebo-controlled study found APAP to be ineffective in treating OA of the knee. 21 Effective analgesia for osteoarthritis pain has been demonstrated in recent short-term controlled clinical studies of codeine and oxycodone, [22] [23] [24] and the use of potent opioids has been endorsed by the American Pain Society (APS) and the American Academy of Pain Medicine (AAPM) for the treatment of chronic nonmalignant pain when other strategies no longer provide adequate relief. 25, 26 The objective of this 90-day study was to investigate the analgesic efficacy and safety, together with the impact on functional outcomes, of controlledrelease (CR) oxycodone versus placebo in patients with OA with uncontrolled persistent pain who were receiving or could not tolerate standard therapy for NSAIDS, APAP, or shortacting opioids.
MATERIALS AND METHODS

Study Design and Patient Selection
This was a double blind, randomized, placebo-controlled, parallel-group study conducted in the United States in accordance with Good Clinical Practice and the Declaration of Helsinki. The study was approved by the Institutional Review Boards of the 9 participating centers (Appendix 1), where it was conducted from June 1997 through August 1998. Each patient signed an informed consent form before enrollment in the study.
To be eligible for the study, patients had to have OA, as defined by the American College of Rheumatology guidelines. 27 Patients selected were experiencing moderate to severe pain in the most affected joint or region, as characterized by: 1) complaints of pain for at least 1 month before day 0 (baseline) or after the patient had discontinued their as necessary opioid; and 2) pain during the week before day 0 that was moderate to severe, defined as an average score of 5 or greater (3 or greater if receiving as necessary opioids) on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). Eligible patients: 1) had been taking NSAIDs or APAP at a therapeutic and/or tolerated (but not as necessary) dose for at least 2 weeks before day 0; 2) were not taking NSAIDs because they were NSAIDintolerant or at high risk for toxicity or complications; or 3) were receiving as necessary oral opioid therapy that was equivalent to #60 mg of oxycodone per day (with or without NSAIDs or APAP for analgesia).
Patients were excluded if they were allergic to opioids, were scheduled to have surgery during the study period, had unstable coexisting disease or active dysfunction, had active cancer, were pregnant or nursing, had a past or present history of substance abuse, were involved in litigation related to their pain, or had received intra-articular or intramuscular steroid injections involving the joint or site under evaluation within 6 weeks prior to baseline.
At the screening visit, demographic information, medical history, and information on baseline medications were obtained; an OA assessment, a physical examination with a vital signs evaluation, and pregnancy test (if applicable) were performed. Patients who met the entry criteria were randomly assigned in double blind fashion to receive either 10-mg tablets of CR oxycodone (OxyContin Ò , Purdue Pharma L.P., Stamford, CT) or matching placebo every 12 hours. The computer-generated randomization code and study drug bottles labeled with randomization numbers were supplied by the sponsor. Patients were permitted to continue their stable NSAID (or APAP) regimen during the study; the dose could be decreased but could not be increased. Patients were not permitted to continue receiving prestudy short-or long-acting opioids. Initial titration to stable dosing was defined as the point at which the patient achieved an average pain intensity score of #4 throughout a 48-hour period on the same dose of study drug. Dose adjustments of study drug were allowed at $24-hour intervals at any time during the study (including after the initial titration was complete). Asymmetric morning and evening dosing was allowed. Doses could be increased (to a maximum of 6 tablets [60 mg] every 12 hours [120 mg per day]) or decreased depending on pain intensity or adverse events.
The first office visit was held after initial titration of the study drug was completed or on day 15, whichever came first; subsequent visits occurred on days 30, 45, 60, and 90. During each visit, patients completed the Brief Pain Inventory (BPI), the patient generated index (PGI), and the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and provided a record of the measure of acceptability of pain medication from their daily diaries, in which they entered ratings of average pain, current pain, and acceptability of pain medication. Adverse events, concomitant medications, and compliance were also assessed at these visits. At the baseline and final visit, patients completed satisfaction scores in addition to the other standard assessments.
Assessment Instruments
The instruments used to measure pain were the BPI, patient-reported acceptability of and satisfaction with medication, the WOMAC, and the PGI. These outcome measures were chosen to characterize the impact of CR oxycodone on multiple outcome domains, including pain reduction, physical functioning, and patient disposition, which are 3 of the core domains for clinical trials of chronic pain treatment mentioned in the Initiative on methods, measurement and pain assessment in clinical trials (IMMPACT). 28 The BPI is a standardized and validated instrument widely used to assess pain intensity and the interference of pain in the patient's life, measured on a scale from 0 to 10. Patients were asked to evaluate their pain on average, ''right now,'' and the interference of their pain with general activity and quality of life items, such as mood, walking, and sleep over the past 24 hours. The BPI, a multidimensional instrument that also incorporates questions about pain relief, has been extensively used to measure the effectiveness of analgesic treatments. 29 Patient-reported satisfaction with pain medication was assessed on a numerical scale from 0 (not at all) to 10 (totally satisfied). Patient-reported acceptability of pain medication was assessed on a numerical scale from 1 (not acceptable) to 6 (totally acceptable).
The WOMAC is an established and validated measure of symptoms and physical disability of patients with OA of the knee and/or hip. 30, 31 The WOMAC has also been used as an outcome measure for populations with pain and/or injury to areas other than the knee or hip, including individuals with lower back pain, ankle arthritis, and meniscal tear. [32] [33] [34] The instrument was developed specifically to evaluate clinically important, patient-relevant changes in pain and dysfunction in patients with OA as a result of treatment intervention. The WOMAC is a self-administered questionnaire evaluating 3 dimensions-pain, stiffness, and physical function over the past 48 hours-on a visual analog scale (VAS) of 0 to 100, with lower scores indicating fewer symptoms or less disability.
The PGI is a validated, self-administered questionnaire that attempts to assess satisfaction with activities selected by the patient as important to improve. The assessment tool has been shown to be a reliable means of quantifying the effect of a medical condition on patients' quality of life. In completing the PGI, the patients were asked at baseline to assign a total of 60 points across 6 areas or activities in their lives that they would like to see improved, with more points implying a greater desire for improvement. At each postbaseline visit, patients rated the 6 areas using a scale from 0 (worst you can imagine) to 100 (exactly as you would like to be). The instrument has been shown to have a high correlation with the widely used and accepted Short-Form 36-Item Health Survey, or SF-36. 35 
Efficacy and Safety Variables
The primary efficacy variables were BPI average pain intensity at stable dosing, WOMAC scores at days 30 and 60, and the number and percentage of patients who discontinued the study due to inadequate pain control.
Secondary efficacy variables included BPI (pain, interference, and function), WOMAC, and PGI (primary activity) scores at each visit throughout the study; time to stable dosing; percentage of patients achieving stable dosing within 30 days; average daily dose at completion of initial titration; average daily dose throughout the study; medication acceptability at each visit; patient satisfaction with pain medication at baseline and the final visit; and ratings of average and current pain intensity from patient diaries.
Safety was evaluated by vital signs and physical examinations, reports of adverse events, and the number and percentage of patients who discontinued from the study due to adverse events.
Statistical Analysis
All variables were evaluated by intent-to-treat (ITT) analysis (ie, including all randomized patients who received at least 1 dose of study drug) in which the last observation was carried forward (LOCF). The sample size calculation was based on the primary comparison of the average pain score between the 2 treatments, using a 2-sample t test. Based on data from previous studies (data on file, Purdue Pharma L.P.), it was assumed that the standard deviation (SD) for the BPI average pain intensity would be 2. Therefore, to obtain a significance level of a = 0.05 to detect a difference of D = 1.25 with 80% power, a minimum of 82 total patients, or 41 patients per group, was needed.
Demographic and other baseline variables were compared between treatment groups using the Student t test for continuous variables and the Fisher exact test for categorical variables. The primary analysis of average pain at stable dosing was based on BPI average pain scores at visit 2 (stable dosing or day 15) for those patients who achieved stable dosing, at visit 3 (day 30) for patients who did not achieve stable dosing or achieved stable dosing on a date later than visit 2, or at the final visit for those patients who discontinued at visit 2 or 3. The composite BPI physical function scores were calculated by averaging the BPI interference scores for general activity, walking ability, and normal work; the composite BPI interference scores were obtained by averaging all of the BPI interference subscale scores. 29 Composite WOMAC scores were calculated by averaging the scores from all 3 subscales: pain, stiffness, and physical function. 30 One primary activity was selected from among the 5 areas or activities that patients rated most important on the PGI for analysis prior to unblinding the data.
Treatment effects on average pain intensity at stable dosing and patient satisfaction at the end of the study, as well as WOMAC, BPI, and patients' diary variables at each scheduled visit, were compared using analysis of covariance (ANCOVA). Study center effect, treatment effect, and treatment-by-center interaction were included in the ANCOVA model. Covariates included baseline data, age group, and gender. The Student t test was used to analyze changes from baseline in patient satisfaction and in the BPI within treatment groups. A repeatedmeasures ANCOVA was applied to compare WOMAC scores between groups after 30 and 60 days of treatment (baseline data, study center, age group, gender, treatment, treatment-bycenter interaction, and visit were included in the model) and to investigate the relationship between the pain scores and the acceptability of treatment. The repeated-measures ANCOVA comparing WOMAC scores between groups after 30 and 60 days of treatment was also performed on a subset of ITT population: those patients with OA of the hip, knee, lower back, and lower extremities. The Fisher exact test was used to compare the percentage of patients in each group who discontinued due to treatment failure or adverse events. The number of patients who achieved stable dosing within 30 days was compared between treatment groups using the Fisher exact test. The Kaplan-Meier analysis was employed to estimate the distribution of time to stable dosing; distributions between groups were compared using a log-rank test. Treatment effects were tested with a 2-sided hypothesis at a = 0.05. Data are presented as least squares (LS) means 6 standard error (SE) except where otherwise indicated.
Adverse events (AEs) were summarized using Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART Ò ). 36 
RESULTS
Patient Demographics
Of 109 patients enrolled, 107 were included in the ITT and safety populations (Fig. 1) . Two patients were randomized to placebo, but withdrew from the study prior to receiving the placebo study drug.
Demographic and baseline characteristics of the 107 patients included in the ITT and safety populations are summarized in Table 1 . The patient population was predominantly female and white with an average age of 63 years. No statistically significant differences were found between the CR oxycodone group and the placebo group for any demographic or baseline characteristic. Mean BPI scores and WOMAC measurements at baseline were also similar in both treatment groups. Within both treatment groups, approximately 40% were not opioid exposed at study entry. A total of 37% were taking ''weak'' opioids (tramadol 15%, propoxyphene 14%, and codeine 8%), and 22% were taking short-acting opioids. At baseline, more than 80% of the patients in each treatment group were receiving stable NSAIDs and/or APAP therapy, either as single entities or as combination agents.
Primary Efficacy Variables
Significantly lower average pain scores at stable dosing, as measured by the BPI average pain intensity subscale, were observed in the CR oxycodone group (5.1 6 0.3 vs. 6.0 6 0.3; P = 0.042) compared with the placebo group.
The results of the WOMAC subscales and composite scores on days 30 and 60 also indicated a treatment effect of CR oxycodone compared with the results for placebo ( Table 2 ). The WOMAC analysis was repeated using a subset of the ITT population, yielding similar results (Table 2) ; this subset included patients with hip, knee, lower back, or lower extremity OA. The differences between treatment groups were statistically significant for pain, stiffness, and difficulty in physical function, as well as for the composite score.
The adjusted mean changes (mm) in scores from baseline at days 30 and 60 in the CR oxycodone group were as follows: for pain, 213.0 and 217.8; for stiffness, 215.8 and 221.7; for physical function, 212.4 and 217.1; and for the composite score, 213.8 and 218.9, respectively. These changes were significantly greater than those of the placebo group at days 30 and 60, in which the changes (mm) observed in scores from baseline were as follows: for pain, 24.1 and 22.4; for stiffness, 0.3 and 0.1; for physical function, 23.2 and 23.8; and for the composite, 22.4 and 22.1, respectively.
The number and percentage of patients who discontinued due to inadequate pain control were statistically significantly 
Secondary Efficacy Variables Pain
Brief Pain Inventory scores for patients receiving CR oxycodone treatment were significantly lower for pain intensity and interference with function and higher for pain relief, compared to scores for patients receiving placebo at all of the treatment visits. Differences in average pain intensity scores between the 2 treatment groups ranged from 0.9 to 1.4 (Fig. 2) . During treatment, mean scores for average pain, pain right now, and worst pain were significantly lower in the CR oxycodone group compared to the placebo group at all visits (days 15 and 90 are presented in Table 3 ). In addition, scores for least pain (days 30, 60, and 90) were significantly lower in the CR oxycodone group, whereas scores for pain relief (all treatment visits) were significantly higher in the CR oxycodone group compared with the placebo group ( Table 3) . The WOMAC pain subscale scores corroborated the treatment effect observed on the BPI average pain intensity subscale (Fig. 2) .
Nearly 38% of the patients in the CR oxycodone treatment group achieved at least 30% pain relief at the end of 90 days, as compared to 17.6% of the patients in the placebo group (P = 0.031). Nearly 20% of the patients in the CR oxycodone treatment group achieved at least 50% pain relief at the end of 90 days, as compared to 5.9% of the patients in the placebo group (P = 0.045).
The number of patients that would need to be given treatment with CR oxycodone for one of them to achieve at least a 30% improvement in average pain (number of patients needed to treat, NNT) equals 5.0 at the day 90 study visit. The NNT for a 50% improvement in average pain at the day 90 visit equals 7.3 patients.
Physical Functioning
The same maintenance of effect observed on the WOMAC pain subscale was seen on the other WOMAC subscales (stiffness and difficulty in physical function) and the composite scale. These WOMAC scores were significantly reduced in the CR oxycodone group at all treatment visits. At day 90, significantly reduced scores for stiffness and difficulty in physical function and in the composite score were observed in the CR oxycodone group (48.7 6 3.2, 45.4 6 2.6, and 46.6 6 2.7, respectively, vs. 68.9 6 3.5, 58.6 6 2.9, and 62.2 6 3.0, respectively, for placebo; P , 0.001 for all scales).
Controlled-release oxycodone statistically significantly reduced interference caused by pain with various daily activities as measured on the BPI interference subscales (Table 4) . At all treatment visits, the mean scores for interference were statistically significantly lower in the CR oxycodone group than in the placebo group for general activity, mood, normal work, sleep, and enjoyment of life. For walking ability, the ‡For this study, tramadol and propoxyphene were considered opioids because of cross-tolerance. §From 0 (no pain) to 10 (pain as bad as you can imagine). k Composite score calculated from pain, stiffness, and difficulty in physical function scores; assessments made using a 100-mm visual analogue scale ranging from 0 (no pain/stiffness/difficulty) to 100 (extreme pain/stiffness/difficulty). differences were statistically significant between the CR oxycodone and the placebo groups at all treatment visits except at day 30; for relations with others, the differences were statistically significant at days 60 and 90. For the composite BPI interference scale and the composite BPI physical function scale, the scores were statistically significantly lower in the CR oxycodone group than in the placebo group at all treatment visits (Fig. 3, Table 4 ).
The PGI scores reflected improvement in the primary activity (chosen by the sponsor prior to unblinding the data) among patients taking CR oxycodone during the study. At days 30 and 45, the PGI scores were 46.4 6 2.9 and 51.2 6 3.1, respectively, for CR oxycodone versus 37.6 6 3.3 and 39.7 6 3.5, respectively, for placebo (for day 30, P = 0.027; for day 45, P = 0.007).
Dosing
The time to achieve stable dosing was significantly shorter in the CR oxycodone group (12 days) compared to greater than 30 days in the placebo group (P # 0.001). More patients achieved stable dosing within 30 days in the CR oxycodone group (68%) than in the placebo group (31%). The daily average dosage of study drug at the time of stable dosing was 4.4 6 0.5 tablets (44 6 5 mg) for the CR oxycodone group, compared to 5.3 6 0.6 tablets for the placebo group. The number of tablets taken per day plateaued in both treatment groups after visit 3, and the average CR oxycodone dose was 57 mg per day for the remainder of the study.
Acceptability and Satisfaction
Scores for patient acceptability of pain medication and satisfaction with pain medication were significantly higher for patients receiving CR oxycodone. Patients' self-reports of the acceptability of pain medication showed significantly increased ratings for those in the CR oxycodone group at all study visits. At the end of the 90-day treatment period, the CR oxycodone and the placebo groups registered statistically significant differences in scores for acceptability of pain medication (P = 0.002) and satisfaction with pain medication (P , 0.001) (Fig. 4) .
Daily Measurements
The daily reports in the patient diaries corroborated instrument measurements demonstrating greater decreases in †From 0 (does not interfere) to 10 (completely interferes). ‡The interference composite score was calculated by averaging all of the interference subscale scores. §The physical function composite score was calculated by averaging interference with general activity, walking ability, and normal work scores. †For all subscales except pain relief, 0 denotes ''no pain'' and 10, ''pain as bad as you can imagine.'' For pain relief, 0 denotes ''no relief'' and 100, ''complete relief.'' ‡Denotes score at time stable pain control was achieved, or on day 15, whichever occurred first. §For visit 2, n = 55 for change from baseline. For day 90, n = 54 for change from baseline.
average pain intensity and ''pain right now'' for the CR oxycodone group, together with increased acceptability of therapy associated with CR oxycodone treatment versus administration of placebo.
Safety
The common AEs (incidence $10% of patients) observed in the CR oxycodone were those typical of an oral opioid analgesic (Table 5) . A total of 28 (55%) patients in the placebo group and 52 (93%) of patients in the CR oxycodone group reported adverse events. Most AEs in both treatment groups were mild or moderate in intensity, had resolved by termination of the study, and did not require a change in study drug dose or other treatment. The number of patients needed to harm (NNH) equals 2.3 patients. The NNH was computed by examining those patients with 1 or more of the following adverse events (constipation, somnolence, dizziness, pruritus, headache, diarrhea, vomiting, or sweating) over the study period. The NNH for AEs leading to study discontinuation is 3.15.
No serious AEs were reported in the placebo group. Three patients in the CR oxycodone group had serious AEs: dizziness and difficulty with speech in the first patient; phlebitis in the second; and influenza, difficulty in swallowing, gastric dysmotility, and dehydration in the third patient. Dehydration, swallowing difficulty, and gastric dysmotility were considered to be related to the study drug.
Twenty patients (36%) discontinued from the study due to adverse events in the CR oxycodone group compared to 2 patients (4%) in the placebo group (P , 0.001). Constipation, nausea, somnolence, and dizziness were the most common AEs leading to discontinuation in the CR oxycodone group. There were no deaths.
DISCUSSION
This study was conducted in a well-defined population who met the criteria for OA as defined by the American College of Rheumatology guidelines. 27 The primary outcome measures of this study demonstrated that CR oxycodone was superior to placebo in reducing average pain in the joint or other region most affected by OA. These results are consistent with previous placebo-controlled trials that have demonstrated that CR oxycodone is an effective treatment of moderate to severe OA pain. 22, 24 The recent American Pain Society Guidelines specifically advise use of mu-agonist opioids, either as single agents or combined with an NSAID or APAP, for treatment of moderate to severe osteoarthritis and rheumatoid arthritis (RA) pain when other treatments have failed to provide adequate relief. 26 The study was powered appropriately and used a randomized double blind design to limit possible confounding or bias. A potential source of bias in this study was that no measures were taken to blind investigators and patients when patients reported AEs. However, an examination of the data shows that the difference between the treatment groups for the day 90 BPI and WOMAC measurements was similar in magnitude for both the opioid naive and opioid experienced cohorts. This study also documented improvements in physical function, in addition to reduced pain levels, as measured by the WOMAC subscales and composite scores. Improvements in WOMAC scores achieved by day 90 ranged from 13.5 mm to 17.9 mm across scales and are comparable or superior to the results from other studies of analgesics with established efficacy in OA treatment, such as ibuprofen (2400 mg per day), meloxicam (15 mg per day), and diclofenac (50 mg twice daily). [37] [38] [39] The data from one of these studies suggest that mean changes of approximately 9 to 12 mm on the 100-mm WOMAC scales reflect clinically relevant improvements among patients with hip and knee OA. 37 A limitation of this study is that the WOMAC OA Index was validated for individuals with OA of the hip or knee, whereas approximately 52% (56 out of 107) of the study patients had OA other than of the hip and knee. However, the WOMAC scales have been used in previous studies of individuals with OA of the lower back and lower extremities. 32, 33 A subsequent analysis including the 89 patients (83%) with OA of the hip, knee, lower back, or lower extremities showed a treatment effect for CR oxycodone on all of the WOMAC scales.
The results of the primary and secondary efficacy variables were consistent across measurements for both treatment groups. The WOMAC scores were observed to decrease, as did scores for pain-associated interference in all areas of daily activities, as measured by the BPI, for patients treated with CR oxycodone compared to those treated with placebo. The correlations between the pain and function dimensions on the BPI and WOMAC scales have been recently reported in patients with OA. 40 In this study, at baseline, the BPI score for ''worst pain'' was approximately 8, an intensity level at which it has been shown that pain begins to interfere with and significantly affect relations with others, in addition to normal activities. 29 In this study, CR oxycodone treatment significantly reduced interference of pain with relations with others from high baseline levels. Equally important, the statistically significant level of reduction found with CR oxycodone treatment was also observed in patients for whom pain resulted in mild interference with relations with others, with a reported score of 4.0 at baseline: by 60 days, the adjusted score was 2.8, a significant reduction; and at 90 days, 2.9. Moreover, CR oxycodone treatment also produced improvements in the primary activity measurement of the PGI, which reflects improvement in activities chosen by the patients, compared to placebo administration, also corroborating the results observed in both the BPI and the WOMAC. Significant pain control across all outcome scales was associated, for patients in the CR oxycodone group, with higher ratings of acceptability of pain medication compared to patients in the placebo group. The significant pain control and higher acceptability ratings were substantiated by several findings: fewer CR oxycodone patients discontinued from the study due to inadequate pain control compared to patients in the placebo group; patients taking CR oxycodone stabilized their dose level early and took less study drug overall throughout the study compared to patients taking placebo; and patients taking CR oxycodone reported significant satisfaction with their pain therapy in contrast to patients receiving placebo. Approximately two-thirds of the patients did not complete participation in the study, with pain scores higher, as expected, among those patients that discontinued from the study. The results show that the treatment effects between the CR oxycodone and the placebo groups were similar between both the completer and noncompleter cohorts. Table 6 shows the mean day 90 BPI average pain and interference measurement scores for completed patients and those that did not complete the study. Table 7 shows the mean day 90 WOMAC pain, stiffness, physical function, and composite scores for completed patients and those that did not complete the study. The magnitude of the differences in favor of the CR oxycodone treatment group was comparable when examining the completer, noncompleter, or the total ITT cohorts.
In this study, at the baseline assessment, the majority of patients (greater than 80%) were taking stable doses of NSAIDs or APAP either alone or in a combination product containing an opioid and yet were experiencing moderate to severe pain. Pain reduction was observed when NSAIDs or APAP were used concomitantly with CR oxycodone, suggesting that CR oxycodone provided additional benefit when added to NSAIDs or APAP. In this study, a majority approximately 60% of the patients had a history of prior use of opioids, which was permitted by the protocol, suggesting that an appropriate population for the use of CR opioids was enrolled in the study. The use of placebo as a comparator could be a potential limitation of the study; however, the patients who enrolled in the study were required to be taking NSAID or APAP at a maximally tolerated dose or were intolerant of or at high risk for this therapy and/or taking short-acting opioids. Patients were permitted to continue their stable NSAID/APAP therapy, thus the placebo group is representative of a usual care group. It is of interest that the placebo group titrated their average dose of study drug to approximately 5.4 tablets per day (compared to 4.4 tablets for the CR oxycodone group), possibly due to a placebo effect.
In this study, constipation was to be treated prophylactically with stimulant laxatives and stool softeners, and persistent nausea was to be treated with antiemetics. The most frequent AEs reported in the CR oxycodone group in this study were constipation and nausea, consistent with use of opioid analgesics. More than one-third of patients taking CR oxycodone discontinued because of adverse events, suggesting that more aggressive treatment of constipation and nausea might improve the discontinuation rate. Effective opioid therapy should be accompanied by early recognition and aggressive treatment of these events. Constipation should be anticipated and treated prophylactically with a stimulant laxative and/or stool softener. 41 The potential for tolerance is a concern among both patients and health-care providers. In this study, daily doses of CR oxycodone averaged 57 mg. Doses thus remained relatively low despite allowable increases of more than 3 times the stabilized dose (120 mg per day), which suggests that patients were not developing tolerance. This finding is similar to dose levels in another study in which the average daily dose at the end of titration was approximately 40 mg per day. 22 (The average placebo ''dose'' also plateaued below the maximum permitted dose of 12 tablets per day, but at a higher level [approximately 7.4 tablets per day] than with CR oxycodone.)
This 90-day study demonstrated that treatment with CR oxycodone of patients with OA who had persistent moderate to severe pain uncontrolled by standard therapy resulted in significant pain control and improvements in physical functioning. These data suggest that CR oxycodone provided an additional benefit beyond the improvements observed with NSAIDs or APAP alone. Controlled-release oxycodone treatment produced adverse events typically seen with the use of an opioid analgesic and was not associated with any significant safety concerns. Data from this study support current treatment recommendations from pain specialists that selected groups of patients would benefit from treatment with opioid analgesics. 26 Among patients with OA, opioid analgesics would benefit those with moderate to severe persistent pain who are unresponsive or intolerant to nonopioid medications such as APAP, NSAIDs, or COX-2 inhibitors or for whom monotherapy is insufficient. The large number of patients that discontinued in this study could have influenced the results. However, the patients that completed the study displayed a similar degree of treatment difference in favor of the CR oxycodone treatment, as did those patients that discontinued from the study. 
